HLS Therapeutics Inc. surprises investors with a significant earnings beat, showcasing resilience in a challenging market.
On August 12, 2026, HLS Therapeutics Inc. (HLS.TO) reported its Q2 2026 earnings, revealing a notable surprise in its earnings per share (EPS). The company posted an EPS of -$0.03, exceeding analyst expectations of -$0.08 by 62.5%. This performance reflects a positive trend in HLS's financial health amidst a competitive pharmaceutical landscape.
Recent earnings trend
Advertisement
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeAdvertisement
Market cap
$119.78M
52W high
$5.76
52W low
$3.81
1W change
-3.40%
Beta
0.86
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 81.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.21
+81.3% Upside
Current Price
C$3.98
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
29.7%
Annualized
90-Day Vol
24.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.33
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.75 | C$3.38 – C$4.16 |
| 60 trading days | C$3.53 | C$3.06 – C$4.09 |
| 90 trading days | C$3.33 | C$2.79 – C$3.98 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 2 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 2 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-12 | — | -0.0600 | — |
| 2026-06-30 | 2026-08-12 | -0.0300 | -0.0800 | +62.5% |
| 2026-03-31 | 2026-05-06 | -0.0700 | -0.1200 | +41.7% |
| 2025-12-31 | 2026-03-12 | -0.0400 | -0.0300 | -33.3% |
| 2025-09-30 | 2025-11-13 | -0.1200 | -0.0700 | -71.4% |
| 2025-06-30 | 2025-08-14 | -0.0900 | -0.0800 | -12.5% |
Advertisement
Investor takeaway: Investors should consider HLS Therapeutics' recent earnings beat as a sign of potential recovery and growth, especially with its ongoing product developments and strategic initiatives in the healthcare sector.
Bull case
HLS's EPS surprise of 62.5% shows a significant improvement compared to previous quarters, suggesting a possible turnaround in earnings performance. This indicates that the company is becoming more efficient in its operations and could be on track for future profitability, particularly with net sales growth from key products like Vascepa.
Bear case
Despite the earnings surprise, HLS is still facing challenges with a negative EPS and profit margin. This highlights the ongoing difficulties the company has in achieving sustained profitability.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
